XSpray Pharma AB (XSPRAY) — Cash Flow-to-Debt Ratio
XSpray Pharma AB (XSPRAY) has a Cash Flow-to-Debt Ratio of -0.18x as of March 2026, meaning its operating cash flow of Skr-30.68 Million could theoretically repay 0% of its total liabilities (Skr167.03 Million) in one year. See cash generation quality of XSpray Pharma AB to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
XSpray Pharma AB Cash Flow-to-Debt Ratio (2015–2025)
Historical debt coverage capacity for XSpray Pharma AB across 11 annual periods. Also explore XSPRAY net asset momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for XSpray Pharma AB (2015–2025)
Year-by-year debt coverage analysis for XSpray Pharma AB. For market capitalisation and broader financial context, see XSpray Pharma AB (XSPRAY) market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (SEK) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -1.17x | Skr-193.16 Million | Skr164.70 Million | ▲ +8.6% |
| 2024 | -1.28x | Skr-222.37 Million | Skr173.25 Million | ▲ +54.6% |
| 2023 | -2.83x | Skr-203.28 Million | Skr71.85 Million | ▲ +24.5% |
| 2022 | -3.75x | Skr-110.18 Million | Skr29.41 Million | ▼ -126.1% |
| 2021 | -1.66x | Skr-51.61 Million | Skr31.15 Million | ▲ +21.3% |
| 2020 | -2.10x | Skr-47.79 Million | Skr22.72 Million | ▼ -65.7% |
| 2019 | -1.27x | Skr-34.24 Million | Skr26.96 Million | ▲ +22.9% |
| 2018 | -1.65x | Skr-17.75 Million | Skr10.77 Million | ▲ +14.1% |
| 2017 | -1.92x | Skr-11.04 Million | Skr5.75 Million | ▼ -492.8% |
| 2016 | -0.32x | Skr-1.74 Million | Skr5.39 Million | ▲ +93.3% |
| 2015 | -4.82x | Skr-12.96 Million | Skr2.69 Million | — |